Trial Profile
Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® ) During Consolidation
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Oct 2022
Price :
$35
*
At a glance
- Drugs Arsenic trioxide (Primary) ; Cytarabine; Cytarabine; Idarubicin; Mercaptopurine; Methotrexate; Mitoxantrone; Tretinoin
- Indications Acute promyelocytic leukaemia
- Focus Biomarker; Therapeutic Use
- 03 Oct 2022 Status changed from active, no longer recruiting to completed.
- 23 Mar 2021 Status changed from completed to active, no longer recruiting.
- 02 Aug 2017 Primary endpoint of event-free survival has been met, according to results published in the Journal of Clinical Oncology.